中华临床医师杂志(电子版)
中華臨床醫師雜誌(電子版)
중화림상의사잡지(전자판)
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
12期
5432-5438
,共7页
费贤树%曾谊%林云霞%宋梅梅
費賢樹%曾誼%林雲霞%宋梅梅
비현수%증의%림운하%송매매
分枝杆菌,牛%结核,胸膜%Meta分析
分枝桿菌,牛%結覈,胸膜%Meta分析
분지간균,우%결핵,흉막%Meta분석
Mycobacterium bovis%Tuberculosis,pleural%Meta-analysis
目的评价母牛分枝杆菌菌苗辅助治疗结核性胸膜炎的疗效与安全性。方法检索中国生物医学文献数据库中文科技期刊全文数据库、万方数据库、Pubmed、Embase、Biosis,纳入比较母牛分枝杆菌辅助治疗组与对照组的随机对照临床试验,采用Stata 12.0进行Meta分析。结果最终纳入9个随机对照临床试验。 Meta分析结果显示,微卡辅助治疗组与对照组相比,胸水吸收情况[ RR=1.12,95% CI (1.07.1.17),P<0.001],胸膜增厚情况[RR=0.28,95% CI(0.18,0.43),P<0.001]1年期复发率[RR=1.12,95%CI(1.05,1.19),P<0.001]的差异均有统计学意义。未报道与微卡临床应用相关的严重系统性不良反应。结论母牛分枝杆菌用于辅助治疗结核胸膜炎,是一种安全有效的药物。为获得更佳的循证医学证据,建议开展更多大样本、多中心、长期随访的高质量临床随机对照试验。
目的評價母牛分枝桿菌菌苗輔助治療結覈性胸膜炎的療效與安全性。方法檢索中國生物醫學文獻數據庫中文科技期刊全文數據庫、萬方數據庫、Pubmed、Embase、Biosis,納入比較母牛分枝桿菌輔助治療組與對照組的隨機對照臨床試驗,採用Stata 12.0進行Meta分析。結果最終納入9箇隨機對照臨床試驗。 Meta分析結果顯示,微卡輔助治療組與對照組相比,胸水吸收情況[ RR=1.12,95% CI (1.07.1.17),P<0.001],胸膜增厚情況[RR=0.28,95% CI(0.18,0.43),P<0.001]1年期複髮率[RR=1.12,95%CI(1.05,1.19),P<0.001]的差異均有統計學意義。未報道與微卡臨床應用相關的嚴重繫統性不良反應。結論母牛分枝桿菌用于輔助治療結覈胸膜炎,是一種安全有效的藥物。為穫得更佳的循證醫學證據,建議開展更多大樣本、多中心、長期隨訪的高質量臨床隨機對照試驗。
목적평개모우분지간균균묘보조치료결핵성흉막염적료효여안전성。방법검색중국생물의학문헌수거고중문과기기간전문수거고、만방수거고、Pubmed、Embase、Biosis,납입비교모우분지간균보조치료조여대조조적수궤대조림상시험,채용Stata 12.0진행Meta분석。결과최종납입9개수궤대조림상시험。 Meta분석결과현시,미잡보조치료조여대조조상비,흉수흡수정황[ RR=1.12,95% CI (1.07.1.17),P<0.001],흉막증후정황[RR=0.28,95% CI(0.18,0.43),P<0.001]1년기복발솔[RR=1.12,95%CI(1.05,1.19),P<0.001]적차이균유통계학의의。미보도여미잡림상응용상관적엄중계통성불량반응。결론모우분지간균용우보조치료결핵흉막염,시일충안전유효적약물。위획득경가적순증의학증거,건의개전경다대양본、다중심、장기수방적고질량림상수궤대조시험。
Objective To evaluate the effectiveness and safety of heat-killed M.vaccae in the treatment of tuberculous pleurisy patients .Methods Such databases,VIP and CNKI Pubmed,Embase,Biosis were searched to collect the randomized controlled trials comparing the effect and safety of the mycobacterium vaccae immunotherapy group and the control group in the treatment of tuberculous pleurisy published before August 2012 .Stata 12.0 software was used for Meta-analysis.Results Nine RCTs involving 658 patients met inclusion criteria were included in meta-analyses .The quality of all studies was in Grade B .The results of meta-analyses showed that mycobacterium vaccae immunotherapy group compared with the control group pleural effusion absorption [ RR =1.12 , 95% CI (1.07.1.17),P<0.001],pleural thickening [RR=0.28,95% CI(0.18,0.43),P<0.001].The relapse rates following one year [RR =1.12,95% CI(1.05,1.19),P <0.001].It was not reported severe complications associated with mycobacterium vaccae vaccine in the treatment of tuberculous pleurisy .Conclusion M.vaccae is a well-tolerated and helpful addition to treatment for tuberculous pleuriy patients .More high quality and multi-center RCTs with larger sample and longer follow-up are proposed .